GS Discovery® is a novel, scalable, transient expression solution driving high titers that rival those of leading off-the-shelf kits. As part of the GS System®, GS Discovery® enables you to use the same tools (cell lines, vectors and GS piggyBac® transposon technology) from discovery through to commercial production.

This supports robust product quality attributes and streamlined development.

You may also be interested in:
Out-Licensed Expression Technologies
Bispecific Antibody
Difficult to Express Proteins
Fabs, Fusion, Scaffold and other Recombinant Proteins
Monoclonal Antibody
GS Gene Expression System®
GS piggyBac® Transposon System
GS Xceed® Gene Expression System
GSquad® Vectors
Mammalian Expression Technologies
GS Discovery®
Author(s):
Peter O'Callaghan, Ph.D.
By clicking "Access Content" you agree to our Legal Disclaimer and the Lonza Privacy and Cookies Policy.

Latest content
Latest briefing from the Knowledge Center
microbial yeast cells - blue
R&D Blog post
Leveraging the potential of XS® Pichia Expression System
One of the most important goals of genetic engineering, especially within the biopharmaceutical...
mAb
Article
Rapid Delivery of Toxicological Material
With increasingly rapid timelines for achieving IND-ready processes, a bottleneck has emerged in the...
man working with microscope in lab,Process Development,Biologics_Slough_18,,lab in slough,tech working in lab with computer,male tech pipetting,tech holding vial,tech working,Cell Iine process development,biologics lab worker, ,Biologics_Slough_29,Biologics , Biologics Slough
Article
Accelerating the Path to Clinical Filing Applications with Rapid Toxicology Material Delivery
The application for investigational new drug (IND) and Clinical Trial Application (CTA) is a key...
CDMO Notes Blog post
Tailoring Analytical Method Development to Minimize the Risk of Post Translational Modification
Overcoming the analytical challenges that post-translational modifications present, getting our...
Article
The Crucial Role of GS-CHO Innovation in Biopharmaceutical Progress
With a long standing track record of success, GS-CHO based expression systems have become the most...
Article
mRNA Research Services To Accelerate Your Project
Monoclonal Antibody
Article
Understanding Glycosylation in Antibodies
Proteins often undergo a variety of post-translational modifications (PTMs) after their initial...
Article
Meet Your Lentiviral Vector Development and Supply Requirements with Xcite® Lenti, an Optimized...
Demand for lentiviral vectors (LVVs) as delivery vehicles for gene therapies is rising...
Fabs & Fc-Fusion whitepaper
Webinar (on-demand)
Accelerating Drug Development for Biologics
Over the past few decades, many novel biotherapeutics seek to enter clinical development in the...
Webinar (on-demand)
Tech Transfer Strategies and Best Practices to Optimize Your Clinical and Commercial Supply
Tech Transfers for biological products, whether they occur from a pharma company, another CMO, or a...
White paper
Lonza as Your Lifecycle Partner for End-to-End Bioconjugate Drug Development
Due to the complicated nature of and expense behind developing and manufacturing antibody drug...
Article
Making More Effective Antibody-Based Immunotherapies with the GS Effex® Cell Line
Antibody-based immunotherapies can mediate cancer cell death via multiple mechanisms, including...